



October 7, 2022

✓ **BSE Limited**

Department of Corporate Services,  
P. J. Towers,  
Dalal Street,  
**MUMBAI - 400 001.**

**National Stock Exchange of India Limited**

Exchange Plaza,  
Bandra Kurla Complex,  
Bandra (East),  
**Mumbai - 400 051.**

*Dear Sir/Madam,*

**Sub: Disclosure pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations).**

We are pleased to enclose a Press Release as regards, Company having reached an agreement with Unitaid, The Aurum Institute, the Clinton Health Access Initiative and other global procurement agencies to support tuberculosis prevention treatment that will be rolled out to 138 countries, including many low- and middle-income countries with a large burden of TB.

This may kindly be considered as a disclosure pursuant to Regulation 30 of the Listing Regulations.

The above is for your information and dissemination.

Thanking you,

**For LUPIN LIMITED**

**R. V. SATAM  
COMPANY SECRETARY  
(ACS - 11973)**

**Encl: a/a**



BSE: 500257

NSE: LUPIN

REUTERS: LUPIN.BO

BLOOMBERG: LPCIN

## Lupin Partners with Global Agencies to Increase Patient Access to Tuberculosis Prevention Treatment

*Makes Rifapentine based treatment available at an affordable price to support TB prevention in low-and middle-income countries*

**Mumbai, October 7, 2022:** Global pharma major, Lupin Limited (Lupin) announced that it has reached an agreement with Unitaid, The Aurum Institute, the Clinton Health Access Initiative (CHAI), and other global procurement agencies to support tuberculosis prevention treatment that will be rolled out to 138 countries, including many low-and middle-income countries with a large burden of TB.

Through this agreement, Lupin will introduce two new formulations, a fixed-dose combination of Rifapentine + Isoniazid and Rifapentine 300 mg standalone tablets, at an affordable price. As a global leader in anti-TB medicines, Lupin is committed to ensuring its products are widely available in all countries and there is equitable access to treatment globally.

“We are committed to enhancing the global access to affordable and high-quality drugs and APIs for the treatment of tuberculosis. We are glad to partner on these important products as this closely aligns with our mission of building better health, globally. Through this, we will further reinforce our long legacy to provide shorter, more patient-friendly treatment options to prevent TB,” said **Nilesh Gupta, Managing Director, Lupin.**

“Lupin continues its accelerated efforts in line with WHO’s The End TB Strategy program. Our expertise in fermentation-based products and backward integration for Rifapentine, enables us to be in a unique position to provide affordable, quality TB prevention and treatment options, and save lives globally,” said **Naresh Gupta, President – API and Global Institution Business, Lupin.**

### About Lupin

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.

The Company enjoys a leadership position in the cardiovascular, anti-diabetic, and respiratory segments and has a significant presence in the anti-infective, gastrointestinal (GI), central nervous system (CNS), and women’s health areas. Lupin is the third-largest pharmaceutical company in the U.S. by prescriptions. The company invested 8.7% of its revenue in research and development in FY22.

## Press Release



BSE: 500257

NSE: LUPIN

REUTERS: LUPIN.BO

BLOOMBERG: LPCIN

Lupin has 15 manufacturing sites, 7 research centers, more than 20,000 professionals working globally, and has been consistently recognized as a 'Great Place to Work' in the Biotechnology & Pharmaceuticals sector.

Please visit [www.lupin.com](http://www.lupin.com) for more information.

Follow us on Twitter: <https://twitter.com/LupinGlobal>

LinkedIn : <https://www.linkedin.com/company/lupin>

Facebook: <http://www.facebook.com/LupinWorld/>

### **For further information or queries please contact:**

#### **Shweta Munjal**

Vice President & Global Head – Corporate Communications

Email: [shwetamunjal@lupin.com](mailto:shwetamunjal@lupin.com)